21.30
0.07 (0.33%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Longboard Pharmaceuticals, Inc. | Bullish | - |
Stockmoo Score
|
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Evercore ISI Group, 275.59%) | Buy |
| Median | 60.00 (181.69%) | |
| Low | 34.00 (Wedbush, 59.62%) | Buy |
| Average | 53.57 (151.50%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 25.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 11 Jul 2024 | 60.00 (181.69%) | Buy | 38.36 |
| 01 May 2024 | 36.00 (69.01%) | Buy | 21.96 | |
| Citigroup | 02 Jul 2024 | 45.00 (111.27%) | Buy | 30.74 |
| Evercore ISI Group | 02 Jul 2024 | 80.00 (275.59%) | Buy | 30.74 |
| 20 Jun 2024 | 57.00 (167.61%) | Buy | 20.14 | |
| Cantor Fitzgerald | 20 Jun 2024 | 60.00 (181.69%) | Buy | 20.14 |
| 03 May 2024 | 60.00 (181.69%) | Buy | 21.38 | |
| B. Riley Securities | 11 Jun 2024 | 36.00 (69.01%) | Buy | 19.09 |
| HC Wainwright & Co. | 11 Jun 2024 | 60.00 (181.69%) | Buy | 19.09 |
| 07 May 2024 | 60.00 (181.69%) | Buy | 22.05 | |
| Wedbush | 03 May 2024 | 34.00 (59.62%) | Buy | 21.38 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jul 2024 | Announcement | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 01 Jul 2024 | Announcement | Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) |
| 10 Jun 2024 | Announcement | Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) |
| 03 Jun 2024 | Announcement | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 06 May 2024 | Announcement | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 02 May 2024 | Announcement | Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |